Literature DB >> 34462815

Clinical characteristics, appropriateness of empiric antibiotic therapy, and outcome of Pseudomonas aeruginosa bacteremia across multiple community hospitals.

Keith Teelucksingh1,2, Eric Shaw3.   

Abstract

There is relatively little contemporary information regarding clinical characteristics of patients with Pseudomonas aeruginosa bacteremia (PAB) in the community hospital setting. This was a retrospective, observational cohort study examining the clinical characteristics of patients with PAB across several community hospitals in the USA with a focus on the appropriateness of initial empirical therapy and impact on patient outcomes. Cases of PAB occurring between 2016 and 2019 were pulled from 8 community medical centers. Patients were classified as having either positive or negative outcome at hospital discharge. Several variables including receipt of active empiric therapy (AET) and the time to receiving AET were collected. Variables with a p value of < 0.05 in univariate analyses were included in a multivariable logistic regression model. Two hundred and eleven episodes of PAB were included in the analysis. AET was given to 81.5% of patients and there was no difference in regard to outcome (p = 0.62). There was no difference in the median time to AET in patients with a positive or negative outcome (p = 0.53). After controlling for other variables, age, Pitt bacteremia score ≥ 4, and septic shock were independently associated with a negative outcome. A high proportion of patients received timely, active antimicrobial therapy for PAB and time to AET did not have a significant impact on patient outcome.
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Bacteremia; Community hospital; Empiric treatment; Pseudomonas aeruginosa

Mesh:

Substances:

Year:  2021        PMID: 34462815     DOI: 10.1007/s10096-021-04342-y

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  25 in total

1.  Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 Update by the Infectious Diseases Society of America.

Authors:  Leonard A Mermel; Michael Allon; Emilio Bouza; Donald E Craven; Patricia Flynn; Naomi P O'Grady; Issam I Raad; Bart J A Rijnders; Robert J Sherertz; David K Warren
Journal:  Clin Infect Dis       Date:  2009-07-01       Impact factor: 9.079

2.  Frequency of occurrence and antimicrobial susceptibility of bacteria isolated from patients hospitalized with bloodstream infections in United States medical centers (2015-2017).

Authors:  Helio S Sader; Mariana Castanheira; Jennifer M Streit; Robert K Flamm
Journal:  Diagn Microbiol Infect Dis       Date:  2019-06-11       Impact factor: 2.803

3.  Risk factors for mortality among patients with Pseudomonas aeruginosa bacteraemia: a retrospective multicentre study.

Authors:  Tanya Babich; Pontus Naucler; John Karlsson Valik; Christian G Giske; Natividad Benito; Ruben Cardona; Alba Rivera; Celine Pulcini; Manal Abdel Fattah; Justine Haquin; Alasdair MacGowan; Sally Grier; Bibiana Chazan; Anna Yanovskay; Ronen Ben Ami; Michal Landes; Lior Nesher; Adi Zaidman-Shimshovitz; Kate McCarthy; David L Paterson; Evelina Tacconelli; Michael Buhl; Susanna Maurer; Jesus Rodriguez-Bano; Isabel Morales; Antonio Oliver; Enrique Ruiz de Gopegui; Angela Cano; Isabel Machuca; Monica Gozalo-Marguello; Luis Martinez-Martinez; Eva M Gonzalez-Barbera; Iris Gomez Alfaro; Miguel Salavert; Bojana Beovic; Andreja Saje; Manica Mueller-Premru; Leonardo Pagani; Virginie Vitrat; Diamantis Kofteridis; Maria Zacharioudaki; Sofia Maraki; Yulia Weissman; Mical Paul; Yaakov Dickstein; Leonard Leibovici; Dafna Yahav
Journal:  Int J Antimicrob Agents       Date:  2019-11-23       Impact factor: 5.283

4.  Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016.

Authors:  Andrew Rhodes; Laura E Evans; Waleed Alhazzani; Mitchell M Levy; Massimo Antonelli; Ricard Ferrer; Anand Kumar; Jonathan E Sevransky; Charles L Sprung; Mark E Nunnally; Bram Rochwerg; Gordon D Rubenfeld; Derek C Angus; Djillali Annane; Richard J Beale; Geoffrey J Bellinghan; Gordon R Bernard; Jean-Daniel Chiche; Craig Coopersmith; Daniel P De Backer; Craig J French; Seitaro Fujishima; Herwig Gerlach; Jorge Luis Hidalgo; Steven M Hollenberg; Alan E Jones; Dilip R Karnad; Ruth M Kleinpell; Younsuck Koh; Thiago Costa Lisboa; Flavia R Machado; John J Marini; John C Marshall; John E Mazuski; Lauralyn A McIntyre; Anthony S McLean; Sangeeta Mehta; Rui P Moreno; John Myburgh; Paolo Navalesi; Osamu Nishida; Tiffany M Osborn; Anders Perner; Colleen M Plunkett; Marco Ranieri; Christa A Schorr; Maureen A Seckel; Christopher W Seymour; Lisa Shieh; Khalid A Shukri; Steven Q Simpson; Mervyn Singer; B Taylor Thompson; Sean R Townsend; Thomas Van der Poll; Jean-Louis Vincent; W Joost Wiersinga; Janice L Zimmerman; R Phillip Dellinger
Journal:  Crit Care Med       Date:  2017-03       Impact factor: 7.598

5.  Impact of inappropriate empiric antimicrobial therapy on outcome in Pseudomonas aeruginosa bacteraemia: a stratified analysis according to sites of infection.

Authors:  E-J Joo; C-I Kang; Y E Ha; S Y Park; S-J Kang; Y M Wi; N Y Lee; D R Chung; K R Peck; J-H Song
Journal:  Infection       Date:  2011-05-19       Impact factor: 3.553

6.  Executive Summary: Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society.

Authors:  Andre C Kalil; Mark L Metersky; Michael Klompas; John Muscedere; Daniel A Sweeney; Lucy B Palmer; Lena M Napolitano; Naomi P O'Grady; John G Bartlett; Jordi Carratalà; Ali A El Solh; Santiago Ewig; Paul D Fey; Thomas M File; Marcos I Restrepo; Jason A Roberts; Grant W Waterer; Peggy Cruse; Shandra L Knight; Jan L Brozek
Journal:  Clin Infect Dis       Date:  2016-09-01       Impact factor: 9.079

7.  Pseudomonas bacteremia. Retrospective analysis of 410 episodes.

Authors:  G P Bodey; L Jadeja; L Elting
Journal:  Arch Intern Med       Date:  1985-09

8.  Pseudomonas aeruginosa bacteremia: an analysis of 123 episodes, with particular emphasis on the effect of antibiotic therapy.

Authors:  Y Siegman-Igra; R Ravona; H Primerman; M Giladi
Journal:  Int J Infect Dis       Date:  1998 Apr-Jun       Impact factor: 3.623

9.  Gram-negative bacteremia upon hospital admission: when should Pseudomonas aeruginosa be suspected?

Authors:  Vered Schechner; Vandack Nobre; Keith S Kaye; Moshe Leshno; Michael Giladi; Peter Rohner; Stephan Harbarth; Deverick J Anderson; Adolf W Karchmer; Mitchell J Schwaber; Yehuda Carmeli
Journal:  Clin Infect Dis       Date:  2009-03-01       Impact factor: 9.079

10.  Diagnosis and Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America.

Authors:  Joshua P Metlay; Grant W Waterer; Ann C Long; Antonio Anzueto; Jan Brozek; Kristina Crothers; Laura A Cooley; Nathan C Dean; Michael J Fine; Scott A Flanders; Marie R Griffin; Mark L Metersky; Daniel M Musher; Marcos I Restrepo; Cynthia G Whitney
Journal:  Am J Respir Crit Care Med       Date:  2019-10-01       Impact factor: 21.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.